Wei Xi
Impact in
-
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
-
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Renal cell carcinoma treatment 23
-
- Renal and related cancers 14
- Epigenetics and DNA Methylation 3
- Co-authors
- Jianming Guo (26 shared papers)Li Liu (20 shared papers)Jiejie Xu (19 shared papers)Qi Bai (18 shared papers)Yu Xia (18 shared papers)Qilai Long (14 shared papers)Yang Qu (15 shared papers)Ying Xiong (15 shared papers)
- Journals
- Oncotarget (7 papers)Scientific Reports (3 papers)BMC Cancer (2 papers)Cancer Management and Research (2 papers)The Journal of Urology (2 papers)
- Partner nations
- China
In The Last Decade
Wei Xi
36 papers receiving 464 citations
Peers
Comparison fields: 5 of 60
- Cancer Research 120
- Oncology 138
- Pulmonary and Respiratory Medicine 163
- Immunology 104
- Molecular Biology 244
Countries citing papers authored by Wei Xi
This map shows the geographic impact of Wei Xi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Xi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Xi more than expected).
Fields of papers citing papers by Wei Xi
This network shows the impact of papers produced by Wei Xi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Xi. The network helps show where Wei Xi may publish in the future.
Co-authors
The 25 scholars most cited alongside Wei Xi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 47 | |
| 2 | 2016 | 46 | |
| 3 | 2016 | 38 | |
| 4 | 2020 | 26 | |
| 5 | 2011 | 22 | |
| 6 | 2016 | 22 | |
| 7 | 2016 | 21 | |
| 8 | 2015 | 20 | |
| 9 | 2016 | 18 | |
| 10 | 2017 | 18 | |
| 11 | 2016 | 16 | |
| 12 | 2016 | 15 | |
| 13 | 2016 | 15 | |
| 14 | 2017 | 14 | |
| 15 | 2016 | 13 | |
| 16 | 2017 | 13 | |
| 17 | 2020 | 12 | |
| 18 | 2020 | 12 | |
| 19 | 2017 | 10 | |
| 20 | 2017 | 9 |
About Wei Xi
Wei Xi is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Cancer Research and Immunology, having authored 38 papers that have together received 473 indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (23 papers), Renal and related cancers (14 papers), Cancer Immunotherapy and Biomarkers (7 papers), Cancer Genomics and Diagnostics (5 papers), Epigenetics and DNA Methylation (3 papers), Immunotherapy and Immune Responses (3 papers), Cancer Mechanisms and Therapy (3 papers) and MicroRNA in disease regulation (2 papers). The work is most often cited by research in Cancer Research (120 citations), Oncology (138 citations), Pulmonary and Respiratory Medicine (163 citations), Immunology (104 citations) and Molecular Biology (244 citations). Wei Xi has collaborated with scholars based in China. Frequent co-authors include Jianming Guo, Li Liu, Jiejie Xu, Qi Bai, Yu Xia, Qilai Long, Yang Qu, Ying Xiong, Jiajun Wang and Xiaoyi Hu. Their work appears in journals such as Oncotarget, Scientific Reports, BMC Cancer, Cancer Management and Research and The Journal of Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.